Ignite Creation Date:
2025-12-24 @ 1:53 PM
Ignite Modification Date:
2026-01-02 @ 3:36 PM
Study NCT ID:
NCT01357395
Status:
COMPLETED
Last Update Posted:
2024-08-02
First Post:
2011-05-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
Sponsor:
Astex Pharmaceuticals, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-05
Start Date Type:
None
Primary Completion Date:
2012-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-05-28
Completion Date Type:
ACTUAL
First Submit Date:
2011-05-17
First Submit QC Date:
None
Study First Post Date:
2011-05-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2017-10-24
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2024-08-01
Last Update Post Date:
2024-08-02
Last Update Post Date Type:
ACTUAL